Treatment strategies for pemphigus vulgaris in Japan.
BACKGROUND
Pemphigus vulgaris is a severe and possibly fatal skin disease with blisters and erosions on the oral mucosae and the skin.


OBJECTIVE
To identify the best treatments currently used for pemphigus vulgaris.


METHODS
The results of previously published studies were summarized.


CONCLUSIONS
The use of systemic steroid therapy is indispensable for the treatment of pemphigus vulgaris. Some patients can be treated only with this therapy; however, other cases do not respond to this regimen. For such intractable pemphigus vulgaris cases, a variety of regimens are used in addition to systemic steroid therapy. These include plasmapheresis, steroid pulse therapy, intravenous immunoglobulin (IVIG), various immunosuppressive agents (such as azathioprine, cyclophosphamide, ciclosporin, mycophenolate mofetil and mizoribine) and anti-CD20 monoclonal antibody (rituximab). When these adjuvant therapies are used, we should always be careful for the severe infectious diseases, except for IVIG. In the most intractable cases, a combination of these adjuvant treatments may be used.
Kurume University School of Medicine, Department of Dermatology, 67 Asahimachi, Kurume, Fukuoka 830-0011, Japan. hashimot@med.kurume-u.ac.jp
Takashi
T
Hashimoto
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007564:Japan; D010392:Pemphigus / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D010956:Plasmapheresis; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D000069283:Rituximab; D011239:Prednisolone